Secondary prevention of atherothrombotic cerebrovascular events.
Secondary prevention of atherosclerotic stroke and transient ischemic attack includes both conventional approaches to vascular risk factor management (blood pressure lowering, cholesterol reduction with statins and smoking cessation), antiplatelet therapy and more specific interventions, such as carotid revascularization. The objective of this review is to discuss effective interventions for optimal secondary prevention of atherosclerotic stroke.
Stroke Unit and Division of Cardiovascular Medicine, University of Perugia, Santa Maria della Misericordia Hospital, Sant'Andrea delle Fratte, 06126 - Perugia, Italy. mpaciaroni@med.unipg.it.
Maurizio
M
Paciaroni
D000367:Age Factors; D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000627:therapeutic use; D002548:Cerebral Revascularization; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D006973:Hypertension / Q000150:complications / Q000188:drug therapy / Q000378:metabolism; D002537:Intracranial Arteriosclerosis / Q000150:complications / Q000378:metabolism / Q000517:prevention & control* / Q000601:surgery; D002546:Ischemic Attack, Transient / Q000209:etiology / Q000378:metabolism / Q000517:prevention & control* / Q000601:surgery; D050356:Lipid Metabolism / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D012008:Recurrence; D055502:Secondary Prevention / Q000379:methods*
D000925:Anticoagulants; D000959:Antihypertensive Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D010975:Platelet Aggregation Inhibitors